Findings

What do systematic reviews say?

4,860 questions · 64,864 findings · 4,913 reviews · Headline outcomes only

Sort:Best matchNewestHighest certainty Download CSV

No studies found 13,869 · 21.4%GRADE not reported 3,491 · 5.4%Very low 16,300 · 25.1%Low 17,338 · 26.7%Moderate 10,900 · 16.8%High 2,966 · 4.6%

Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.

Any cold therapy vs no cold therapy following total knee replacement

Range of motion at discharge Scale from: 0 to 125. · people undergoing total knee replacement

1 finding from 1 review

Cryotherapy following total knee replacement 2023 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 174 participants
Low

Any cold therapy vs no cold therapy following total knee replacement

Function Standardised scale with positive score indicating a better outcome. Scale from 0 (worst) to 100 (best). · people undergoing total knee replacement

1 finding from 1 review

Cryotherapy following total knee replacement 2023 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 296 participants
Very low

Any cold therapy vs no cold therapy following total knee replacement

Adverse events Adverse events included discomfort, local skin reactions, superficial infections, cold induced injuries and thrombolytic events · people undergoing total knee replacement

It is very uncertain whether any cold therapy changes total adverse eventsAdverse events included discomfort, local skin… compared with no cold therapy following total knee replacement (very low certainty).

1 finding from 1 review

Cryotherapy following total knee replacement 2023 · Cochrane Headline outcomes only
RR 1.3 [0.53, 3.2]
16 studies · 1199 participants
Very low

Any cold therapy vs no cold therapy following total knee replacement

Withdrawals due to adverse events · people undergoing total knee replacement

It is very uncertain whether any cold therapy changes withdrawals due to adverse events compared with no cold therapy following total knee replacement (very low certainty).

1 finding from 1 review

Cryotherapy following total knee replacement 2023 · Cochrane Headline outcomes only
RR 2.71 [0.42, 17.38]
19 studies · 1347 participants
Very low

Anti‐VEGF vs no anti‐VEGF

Proportion of participants with IOP ≤ 21 mmHg, with or without ocular hypotensive medications, 4 to 6 weeks · people with neovascular glaucoma

Anti‐VEGF may leads to higher proportion of participants with IOP ≤ 21 mmHg, with or without… compared with no anti‐VEGF (low certainty).

1 finding from 1 review

Anti‐vascular endothelial growth factor for neovascular glaucoma 2023 · Cochrane Headline outcomes only
RR 1.32 [1.1, 1.59]
1 study · 93 participants
Low

Anti‐VEGF vs no anti‐VEGF

Mean IOP ( · people with neovascular glaucoma

It is very uncertain whether anti‐VEGF changes mean IOP, 4 to 6 weeks compared with no anti‐VEGF (very low certainty).

1 finding from 1 review

Anti‐vascular endothelial growth factor for neovascular glaucoma 2023 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 173 participants
Very low

Anti‐VEGF vs no anti‐VEGF

Visual acuity · people with neovascular glaucoma

It is very uncertain whether anti‐VEGF changes proportion of participants with improvement in visual acuity of 2… compared with no anti‐VEGF (very low certainty).

1 finding from 1 review

Anti‐vascular endothelial growth factor for neovascular glaucoma 2023 · Cochrane Headline outcomes only
RR 2.55 [1.6, 4.08]
1 study · 93 participants
Very low

Anti‐VEGF vs no anti‐VEGF

Proportion of participants with complete regression of new iris vessels, 4 to 6 weeks · people with neovascular glaucoma

Anti‐VEGF may leads to higher proportion of participants with complete regression of new iris… compared with no anti‐VEGF (low certainty).

1 finding from 1 review

Anti‐vascular endothelial growth factor for neovascular glaucoma 2023 · Cochrane Headline outcomes only
RR 2.63 [1.65, 4.18]
1 study · 93 participants
Low

Anti‐VEGF vs no anti‐VEGF

Proportion of participants with relief of pain and resolution of redness, 1 year · people with neovascular glaucoma

The review found no eligible studies for this question.

1 finding from 1 review

Anti‐vascular endothelial growth factor for neovascular glaucoma 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Anti‐VEGF vs no anti‐VEGF

Adverse events assessed in various ways, up to 24 months · people with neovascular glaucoma

1 finding from 1 review

Anti‐vascular endothelial growth factor for neovascular glaucoma 2023 · Cochrane Headline outcomes only
no estimate extracted
6 participants
GRADE not reported

Chemotherapy with bevacizumab followed by bevacizumab maintenance vs chemotherapy alone

Overall survival (OS) · newly‐diagnosed EOC

Chemotherapy with bevacizumab followed by maintenance bevacizumab showed no clear difference in overall survival (OS) compared with chemotherapy alone (moderate certainty).

1 finding from 1 review

Angiogenesis inhibitors for the treatment of epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
HR 0.97 [0.88, 1.07]
2 studies · 2776 participants
Moderate

Chemotherapy with TKI followed by TKI maintenance vs chemotherapy alone

Adverse events (grade ≥ 3) · newly‐diagnosed EOC

Chemotherapy with TKI followed by TKI maintenance probably leads to higher any adverse event grade ≥ 3 compared with chemotherapy alone (moderate certainty).

1 finding from 1 review

Angiogenesis inhibitors for the treatment of epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
RR 1.31 [1.11, 1.55]
1 study · 188 participants
Moderate

Chemotherapy with TKI followed by TKI maintenance vs chemotherapy alone

Hypertension grade ≥ 3 · newly‐diagnosed EOC

Chemotherapy with TKI followed by TKI maintenance may leads to higher hypertension grade ≥ 3 compared with chemotherapy alone (low certainty).

1 finding from 1 review

Angiogenesis inhibitors for the treatment of epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
RR 6.49 [2.02, 20.87]
1 study · 1352 participants
Low

Chemotherapy with TKI followed by TKI maintenance vs chemotherapy alone

Bowel fistula / perforation (grade ≥ 3) · newly‐diagnosed EOC

The review found no eligible studies for this question.

1 finding from 1 review

Angiogenesis inhibitors for the treatment of epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Chemotherapy with TKI (peptide‐Fc fusion protein) followed by TKI maintenance vs chemotherapy alone

Overall survival (OS) · newly‐diagnosed EOC

Chemotherapy with TKI (peptide‐Fc fusion protein) followed by TKI… showed no clear difference in overall survival (OS) compared with chemotherapy alone (moderate certainty).

1 finding from 1 review

Angiogenesis inhibitors for the treatment of epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
HR 0.99 [0.79, 1.25]
1 study · 1015 participants
Moderate

Chemotherapy with TKI (peptide‐Fc fusion protein) followed by TKI maintenance vs chemotherapy alone

Progression‐free survival (PSF) · newly‐diagnosed EOC

Chemotherapy with TKI (peptide‐Fc fusion protein) followed by TKI… showed no clear difference in progression‐free survival (PSF) compared with chemotherapy alone (moderate certainty).

1 finding from 1 review

Angiogenesis inhibitors for the treatment of epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
HR 0.93 [0.79, 1.09]
1 study · 1015 participants
Moderate

Chemotherapy with TKI (peptide‐Fc fusion protein) followed by TKI maintenance vs chemotherapy alone

QoL · newly‐diagnosed EOC

The review found no eligible studies for this question.

1 finding from 1 review

Angiogenesis inhibitors for the treatment of epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Chemotherapy with TKI (peptide‐Fc fusion protein) followed by TKI maintenance vs chemotherapy alone

Adverse events (grade ≥ 3) · newly‐diagnosed EOC

Chemotherapy with TKI (peptide‐Fc fusion protein) followed by TKI… probably leads to lower any adverse event grade ≥ 3 compared with chemotherapy alone (moderate certainty).

1 finding from 1 review

Angiogenesis inhibitors for the treatment of epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 1011 participants
Moderate

Chemotherapy with TKI (peptide‐Fc fusion protein) followed by TKI maintenance vs chemotherapy alone

Hypertension grade ≥ 3 · newly‐diagnosed EOC

The review found no eligible studies for this question.

1 finding from 1 review

Angiogenesis inhibitors for the treatment of epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Chemotherapy with TKI (peptide‐Fc fusion protein) followed by TKI maintenance vs chemotherapy alone

Bowel fistula / perforation (grade ≥ 3) · newly‐diagnosed EOC

The review found no eligible studies for this question.

1 finding from 1 review

Angiogenesis inhibitors for the treatment of epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found